IQVIA Holdings Inc. $IQV Holdings Lessened by Inspire Investing LLC

Inspire Investing LLC decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 23.0% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,817 shares of the medical research company’s stock after selling 8,888 shares during the quarter. Inspire Investing LLC’s holdings in IQVIA were worth $8,016,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Apella Capital LLC increased its holdings in IQVIA by 4.7% in the 3rd quarter. Apella Capital LLC now owns 1,235 shares of the medical research company’s stock worth $319,000 after buying an additional 55 shares during the period. Breakwater Capital Group lifted its stake in IQVIA by 3.2% during the 2nd quarter. Breakwater Capital Group now owns 2,073 shares of the medical research company’s stock valued at $401,000 after acquiring an additional 64 shares during the period. Fortitude Family Office LLC boosted its holdings in shares of IQVIA by 17.2% in the 3rd quarter. Fortitude Family Office LLC now owns 443 shares of the medical research company’s stock valued at $119,000 after acquiring an additional 65 shares during the last quarter. First Growth Capital LLC boosted its holdings in shares of IQVIA by 3.2% in the 1st quarter. First Growth Capital LLC now owns 2,173 shares of the medical research company’s stock valued at $375,000 after acquiring an additional 68 shares during the last quarter. Finally, Chicago Partners Investment Group LLC boosted its holdings in shares of IQVIA by 1.5% in the 1st quarter. Chicago Partners Investment Group LLC now owns 4,635 shares of the medical research company’s stock valued at $812,000 after acquiring an additional 70 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Analysts Set New Price Targets

Several brokerages recently issued reports on IQV. Argus raised their target price on shares of IQVIA from $215.00 to $235.00 in a report on Tuesday, July 7th. Wall Street Zen raised shares of IQVIA from a “hold” rating to a “buy” rating in a report on Saturday, September 12th. TD Cowen increased their price target on IQVIA from $233.00 to $288.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. UBS Group started coverage on IQVIA in a research report on Wednesday, September 30th. They set a “buy” rating and a $345.00 price target on the stock. Finally, Evercore lifted their price objective on IQVIA from $275.00 to $290.00 and gave the company an “outperform” rating in a research note on Tuesday, October 6th. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, IQVIA presently has a consensus rating of “Moderate Buy” and a consensus price target of $278.75.

Insider Activity at IQVIA

In other IQVIA news, insider W. Richard Staub sold 5,500 shares of the company’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider owned 13,312 shares in the company, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Eric Sherbet sold 5,000 shares of the stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider directly owned 20,999 shares in the company, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 15,581 shares of company stock valued at $3,796,021 in the last quarter. 1.70% of the stock is currently owned by insiders.

IQVIA Trading Up 0.4%

IQVIA stock opened at $279.47 on Friday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 12 month low of $154.50 and a 12 month high of $282.98. The stock’s 50 day simple moving average is $263.98 and its two-hundred day simple moving average is $216.43. The firm has a market cap of $46.00 billion, a PE ratio of 34.67, a P/E/G ratio of 2.45 and a beta of 1.17.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The firm had revenue of $4.37 billion during the quarter, compared to analyst estimates of $4.30 billion. During the same period in the previous year, the firm earned $2.81 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts anticipate that IQVIA Holdings Inc. will post 11.54 earnings per share for the current year.

About IQVIA

IQVIA Holdings Inc is a global provider of technology, analytics and contract research services for the life sciences industry. The company helps pharmaceutical, biotechnology and medical device organizations develop, commercialize and improve products by combining healthcare data with advanced analytics, consulting and technology-enabled services.

Its offerings include clinical research and trial management, real-world evidence, healthcare data and analytics, regulatory and safety services, technology platforms, and commercial solutions.